ImmunoCellular And Cancer Treatment's Next Frontier Seeking Alpha Rituximab, (sold under the trade names Rituxan and MabThera) and developed and marketed by Biogen Idec (BIIB) has also garnered success in the treatment of many forms of leukemia and lymphoma. The commercial efficacy of immunotherapy has been proven ... |
